Enveric Biosciences, Inc. · NASDAQ:ENVB

Enveric Biosciences — Investor Presentation (May 2022)

21 slides from Enveric Biosciences's investor presentation, May 24, 2022

  1. Slide 1: Investor Deck May 2022

    CNVERIG Mental Health™ Bl O-S © IE N, © ees Investor Deck May 2022 NASDAQ: ENVB

  2. Slide 2: No Offer or Solicitation

    No Offeror Solicitation This communication Is for informational purposes ony and isnot intended to and does not constitute an offer o sel or the solctation of an offer to buy any secures ora sollctation of any vote or approval. does not constitute @ prospectus or prospectus equivalent document. No o

  3. Slide 3: A platform of next generation psychedelic and cannabinoid medicines

    A platform of next generation psychedelic and cannabinoid medicines We leverage our discovery engine and intellectual property portfolio to create next-generation psychedelics and cannabinoids for the mind and body, with lead products in Cancer. % SES

  4. Slide 4: Management Team

    Management Team Dr. Joseph Tucker Chief Executive Officer & Director Dr. Tucker has 20 years experience in biotechnology, founded and took public biter cortparies'as well as aod company to Tilum Therapeutics Dr. Bob Dagher Chief Medical Officer Seasoned executive physician and rug developer with C-l

  5. Slide 5: Execute on Clinical Assets and Invest in Discovery Assets

    Execute on Clinical Assets and Invest in Discovery Assets Indication Ev101* GBM Ev102 RD EVM101 CRD EVM201_ CRD AP™ “Evaluating strategic alternatives Discovery Preclinical Phase 1 EL I — LL = Phase 2 Phase 3 Major Next Steps Phase 1 IND Submission IND Submission Candidate Nomination Timing Q3 2022

  6. Slide 6: The Platform — Next Generation Medicines

    The Platform — Next Generation Medicines M I N D Psychedelics PSYBRARY™ SEL : Hallucinogenic - Non-Hallucinogenic MIND $70* BILLION Cancer Related Distress $20°BI23 Depression $12* B BODY PTSD $990" M? fs Anxiety $7* B® Market $140 Substance Abuse $31" Bt Opportunity BILLION BODY Psychedelics Cannab

  7. Slide 7: Slide 7

  8. Slide 8: Psychedelics: Market and Investor Validation

    Psychedelics: Market and Investor Validation Market Validation ¢ J&J Spravato first ¢« FDA Breakthrough ¢ Bio-pharma and Life Science approved Psychedelic Status for 2 Drugs Institutional Investors are putting money to work ina + $3B Estimated Peak + MDMA meaningful way in b- Revenue Psychedelics pr

  9. Slide 9: Psychedelics — Treatments for today and tomorrow

    Psychedelics — Treatments for today and tomorrow Optimized NCE for Improved Outcomes Chemically Modified into Prodrugs Classic Psychedelics NASDAQ:ENVB WWW.ENVERIC.COM

  10. Slide 10: Psybrary allows us to potentially expand market exponentially

    Psybrary allows us to potentially expand market exponentially Current Therapist-delivery model limits the Patient Population Served Gen1&2 Psychedelic Model il Psychotherapy with Psychedelics Clinical Environment Pa il Short Term Use Only Hallucinogenic Gen 3 - NCE Model Q000000 Chddlte s— Tradition

  11. Slide 11: Industry Landscape: Rapidly Evolving Sector

    Industry Landscape: Rapidly Evolving Sector Company DemeRx Compass MindMed Cybin Seelos MAPS GH Research Type NASDAQ: ATAI NASDAQ: CMPS NASDAQ: MNMD_ NYSE/NEO: CYBN OTCQB: CLXPF NASDAQ: SEEL Non-profit NASDAQ: GHRS. Indication Opioid Use Disorder Treatment Resistant Depression Multiple Major Depress

  12. Slide 12: Psybrary — Engine for Next Generation Molecules

    Psybrary — Engine for Next Generation Molecules Synthetic ° Biology st een e nee t cece see ceene = Engineered Microbes Blocatalysis - Enzymes ‘ . is 7 Cc ¢G Feed substrate Enzyme catalyzes reaction to change to enzyme non-natural substrate into new product molecules PSYBRARY™ New product molecules

  13. Slide 13: Psybrary offers Massive Diversity Enabling Generation & Drugs

    Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs Broad Intellectual Property Coverage Derivative Molecules Protected Psilocybin & 7 N 10 Filed Patents 1 Million Mescaline/ _ 4 Million+ a a Classic Molecule Patent Filings 5-HT2a () These figures represent the Company's targets. a NAS

  14. Slide 14: PsyAI — Organizing and Analyzing the vast Psybrary

    PsyAI™ — Organizing and Analyzing the vast Psybrary 4 ° a © £ o = Prediction NASDAQ:ENVB WWW.E

  15. Slide 15: Cancer Related Distress (CRD): Opportunity to Improve High Unmet Need

    Cancer Related Distress (CRD): Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path Gen 1 candidate * File IND Q3 ° 71% cancer patients with mental Seientifi : ‘ ; ¢ Begin clinical trial Q4 2022 . tific Evid : hedel egin clinical tria health challenges,

  16. Slide 16: Slide 16

  17. Slide 17: Enveric Spinout Rationale

    E nve ric Ss pi nout Rati ona le the proposed spin-off would create two separate and distinct biotechnology companies wv ENVERI al Monta! Heattn~" Acanna Therapeutics Enveric Biosciences developing next-generation psychedelic-inspired treatments EVM101 EVM201 EVM301 developing innovative cannabinoid

  18. Slide 18: Radiation Dermatitis (RD): $1B Opportunity to Improve High Unmet Need

    Radiation Dermatitis(RD): $1B Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path Enveric novel formulation for RD IND Filing Q4 2022 Protocol & Site PI Finalized Phase 1/2 Study Targeted Q1 2023 Higher Probability Clinical Pathway 50% cancer patients —

  19. Slide 19: Cash and Cash equivalents as of March 31, 2022

    jl Nasdaq :ENvs Cash and Cash equivalents as of March 31, 2022 ¢ Cash On-hand - $21.7 million ¢ Debt- Zero e Jan 2021: $9.5 million ¢ Feb 2021: $12.1 million ¢ Warrant exercise (Mar 2021): $3.3 million ¢ Feb 2022: $10 million ¢ Outstanding shares: 52.6 million ¢ Fully diluted: 93.8 million a NASDAQ:

  20. Slide 20: Expected Catalysts and Milestones

    Expected Catalysts and Milestones EVM201: CRD EVM201: CRD Close Spinoff EVM201: CRD EVM301: CRD EVM301: CRD * Lead Candidate * Begin IND enabling * Completion of Nomination studies Cannabinoid Assets EVM101: CRD * Start Phase I/II EVM201: CRD * Animal Model Study Results Complete Enrollment Phase I/

  21. Slide 21: Building a Discovery & Clinical Platform

    BUILDING A DISCOVERY & CLINICAL PLATFORM TO SERVE THE MIND AND BODY INVESTOR PRESENTATION (NASDAQ: ENVB) For more information please contact: ir@enveric.com

Enveric Biosciences — Investor Presentation (May 2022) on 6ix